Novo Nordisk to Acquire Forma Therapeutics for ~$1.1B
Shots:
- Novo Nordisk to acquire all outstanding shares of Forma Therapeutics’ common stock at $20/share in cash representing a total equity value of $1.1B and a premium of 92% to Forma Therapeutics’ volume-weighted avg. price/share over the past 30 days. The acquisition is expected to close in Q4’22
- The acquisition will strengthen Novo Nordisk’s strategy to advance the scientific presence and pipeline in haemoglobinopathies with the addition of etavopivat for patients with SCD and rare blood disorders
- Etavopivat is a selective PKR activator & is currently being studied in the P-II/III trial for SCD, and P-II trial for transfusion-dependent SCD and another inherited haemoglobinopathy
Ref: GlobeNewswire | Image: Novo Nordisk
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
